1. Home
  2. HLP vs IPHA Comparison

HLP vs IPHA Comparison

Compare HLP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hongli Group Inc.

HLP

Hongli Group Inc.

HOLD

Current Price

$3.49

Market Cap

224.2M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.50

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLP
IPHA
Founded
2021
1999
Country
China
France
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.2M
165.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
HLP
IPHA
Price
$3.49
$1.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
★ 136.8K
33.5K
Earning Date
11-03-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
$51.63
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.17
52 Week High
$3.14
$2.71

Technical Indicators

Market Signals
Indicator
HLP
IPHA
Relative Strength Index (RSI) 85.31 41.16
Support Level $0.85 $1.36
Resistance Level N/A $1.57
Average True Range (ATR) 0.21 0.08
MACD 0.02 0.02
Stochastic Oscillator 94.36 33.33

Price Performance

Historical Comparison
HLP
IPHA

About HLP Hongli Group Inc.

Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: